Is MESO Overvalued?

MESO is now in the Undervalued zone, suggesting that MESO current forward PE ratio of -23.19 is considered Undervalued compare with the five-year average of -10.20.
P/E
EV/EBITDA
P/S
P/B
bubble
P/E

MESO Competitors Valuation Multiple

P/E
EV/EBITDA
P/S

P/E Multiple

Earnings Growth
Market Cap
stocks logo
MESO.O
Mesoblast Ltd
loss
Average P/E:
17.20B
stocks logo
RXRX.O
Recursion Pharmaceuticals Inc
loss
-31.88%
2.65B
stocks logo
EWTX.O
Edgewise Therapeutics Inc
loss
10.02%
2.34B
stocks logo
BEAM.O
Beam Therapeutics Inc
loss
-161.80%
2.36B
stocks logo
TWST.O
Twist Bioscience Corp
loss
28.61%
2.49B
stocks logo
APGE.O
Apogee Therapeutics Inc
loss
-82.41%
2.41B

MESO Revenue Breakdown & PS Ratio Relation

Currency:USD
By Business
By Region
Composition ()
Name
Revenue
Percentage

MESO FAQs

Is MESO currently overvalued based on its P/E ratio?

According to the provided data, MESO's 5-year historical average forward P/E ratio is -10.20. MESO forward P/E ratio is -23.19, which is categorized as Undervalued.

What is the significance of the EV/EBITDA ratio for MESO?

What are the key indicators to watch for MESO's financial performance?

MESO PE Ratio

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalued
Undervalued
5Y Average PE
-10.20
Current PE
-23.19
Overvalued PE
-2.11
Undervalued PE
-18.30

MESO EV/EBITDA Ratio

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalued
Undervalued
5Y Average EV
-20.62
Current EV
-48.81
Overvalued EV
6.41
Undervalued EV
-47.64

MESO P/S Ratio

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalued
Fair
5Y Average PS
29.92
Current PS
28.82
Overvalued PS
48.77
Undervalued PS
11.06

Free Financial AI Agent for Investment

Ask any investment related question and get answer instantly

At what price is MESO undervalued?Is MESO overvalued compared to its competitors?